A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants

Required: EGFR mutation

Presence of EGFR gene mutation

Cannot have received: adjuvant chemotherapy

Exception: ≤ 4 cycles allowed

Have received > 4 cycles of adjuvant chemotherapy

Cannot have received: neoadjuvant therapy

Prior neoadjuvant therapy

Cannot have received: anti-PD-1 therapy

Prior treatment with anti-PD-1

Cannot have received: anti-PD-L1 therapy

Prior treatment with anti-PD-L1/2

Cannot have received: anti-PD-L2 therapy

Prior treatment with anti-PD-L1/2

Cannot have received: anti-CD137 therapy

Prior treatment with anti-CD137

Cannot have received: CTLA-4 modulator

Prior treatment with CTLA-4 modulators

Cannot have received: immunomodulatory agent

Prior treatment with any other immunomodulatory agents

Cannot have received: Chinese herbal medicine with anti-tumor indications

Use of Chinese herbal medicine with anti-tumor indications within 14 days prior to randomization

Cannot have received: growth factor support therapy

Use of growth factor support therapy or have received a transfusion within 14 days prior to randomization

Cannot have received: blood transfusion

Use of growth factor support therapy or have received a transfusion within 14 days prior to randomization

Cannot have received: major surgery

Exception: excluding vascular access procedures

Major surgery within 4 weeks prior to randomization (including surgery for the primary neoplasm, but excluding vascular access procedures), or expected to undergo major surgery during the study